Search Bar & Filters
Found 6 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effectiveness and safety of finerenone compared to a placebo in patients hospitalized with acute decompensated heart failure who have mildly reduced or preserved left ventricular ejection fraction. This international, randomized, double-blind, placebo-controlled Phase 3 trial aims to study how finerenone affects morbidity and mortality in these patients. Participants will be randomly assigned to receive either oral finerenone or a matching placebo. The study is event-driven and will monitor patients for up to approximately 30 months. It includes ongoing evaluation of heart failure events, cardiovascular death, and adverse events related to the study drug. Both groups will be observed throughout this period to compare outcomes. During the trial, participants will undergo regular assessments including monitoring for heart failure events, cardiovascular death, and serious adverse events. The study will also measure changes in symptom scores using the Kansas City Cardiomyopathy Questionnaire at 6 months. Safety and tolerability will be closely tracked, including adverse events leading to discontinuation of the study drug. Participants will be followed for up to 30 months to assess long-term effects.
Actively Recruiting
Researchers are evaluating the effects of therapeutic-dose heparin compared to usual care pharmacological thromboprophylaxis in patients hospitalized with community-acquired pneumonia CAP. The study focuses on the high incidence of hospitalizations due to CAP, which often leads to serious complications including thrombotic events that affect respiratory, cardiac, and other organs. This trial aims to explore whether therapeutic-dose heparin can improve outcomes by targeting inflammatory and thrombotic pathways, a strategy shown to help in COVID-19 but not yet studied in non-COVID-19 CAP. Participants are randomly assigned to one of two groups. One group receives therapeutic-dose low molecular-weight heparin LMWH or unfractionated heparin UFH daily for up to 14 days or until hospital discharge, whichever comes first. The other group receives the usual care thromboprophylaxis dose according to local practice, which is lower than the therapeutic dose. Treatments start as soon as possible after randomization. LMWH is preferred unless contraindicated, with dosing based on patient weight, while UFH may be used in cases of renal impairment. During the study, participants will be monitored for outcomes including survival at 30 days, bleeding events, thrombotic events, mechanical ventilation use, mortality at various timepoints, hospital-free days, and health-related quality of life. The study collects data up to 180 days after treatment. Safety monitoring includes tracking adverse events like bleeding and heparin-induced thrombocytopenia. Participation involves hospital stays expected to last at least 72 hours from randomization, with assessments throughout the treatment period and follow-up extending to 180 days.
Actively Recruiting
Researchers are investigating the impact of adding inclisiran to usual care compared to usual care alone on lowering LDL cholesterol LDL-C in patients hospitalized after an acute cardiovascular event such as a heart attack, ischemic stroke, or urgent coronary revascularization. This multi-country, open-label, randomized clinical trial focuses on patients stabilized and ready for discharge following such events. The study explores the real-world effects on LDL-C levels, patient-reported outcomes, and healthcare resource use. Participants are divided into two groups one receives usual care, which includes physical activity, diet changes, and standard cholesterol-lowering medications like statins and others the other group receives the same usual care plus inclisiran injections at baseline, 90 days, and 270 days. Usual care treatments vary by country but commonly involve statins and other cholesterol-lowering drugs. This phase 4 study measures the effectiveness of inclisiran added to usual care over approximately 11 months. During the study, participants will have assessments at baseline and at day 330 to measure changes in LDL-C and other outcomes such as the proportion of patients achieving specific LDL-C reduction goals. Researchers also track the timing of statin initiation during the study period. Patient health, adherence to treatment, and safety will be monitored throughout. The study concludes for each participant after the last visit and related assessments at day 330.
Actively Recruiting
Researchers are investigating the effects of pre-operative mouthwash and varying oxygen levels during surgery on the rates of pneumonia and surgical site infections in patients undergoing major abdominal surgery. This trial focuses on patients in low and middle-income countries, where postoperative complications are more common and often more severe. The study aims to find ways to reduce these serious complications, which can cause pain, disability, and increased healthcare costs. Participants will be randomly assigned to one of four groups pre-operative chlorhexidine mouthwash combined with high oxygen levels 80-100% FiO2, no mouthwash with high oxygen levels, mouthwash with low oxygen levels 21-30% FiO2, or no mouthwash with low oxygen levels. Treatments are given around the time of surgery, with oxygen delivered during the operation and mouthwash used before surgery. The study includes an internal pilot phase lasting six months to check recruitment and compliance, followed by a larger trial aiming to enroll nearly 13,000 participants. During the study, researchers will monitor participants for up to 30 days after surgery, assessing rates of pneumonia and surgical site infections using CDC definitions. They will also track other outcomes like mortality, repeat surgeries, hospital stay length, return to normal activities, critical care admissions, and healthcare resource use. Follow-up includes evaluating patient recovery and safety, with all data collected to understand how these interventions impact surgical outcomes in these settings.
Actively Recruiting
Researchers are studying two experimental drugs, REGN7508 and REGN9933, in people with atrial fibrillation, a condition where the heart beats irregularly and too fast. The study aims to see how these drugs work to prevent blood clots compared to apixaban, a currently available medicine. The research also looks at potential side effects, how well the drugs reduce stroke risk, drug levels in the blood, and whether the body develops antibodies that might affect the drugs action or safety. Participants will be randomly assigned to receive either REGN7508, REGN9933, or apixaban. All treatments are given according to the study protocol. The study lasts about 12 weeks for the main bleeding safety measurements, with some evaluations continuing up to about 25 weeks to monitor adverse events, antibody development, and blood drug concentrations. Throughout the study, participants will have regular assessments to check for bleeding events, strokes, and treatment side effects. Blood tests will measure drug levels and blood clotting times. Researchers will track safety and effectiveness by comparing bleeding incidents and other outcomes between the different treatments. The total participation time covers the treatment period and follow-up visits up to about 25 weeks.
Actively Recruiting
Researchers are evaluating whether the drug zilebesiran can reduce major cardiovascular events such as cardiovascular death, nonfatal heart attacks, strokes, or heart failure in adults with hypertension that is not well controlled and who have either established cardiovascular disease or are at high risk for it. This is a phase 3, randomized, double-blind, placebo-controlled study that will continue until a targeted number of cardiovascular events have occurred. Participants will receive either 300 mg of zilebesiran or a placebo by subcutaneous injection every six months, in addition to their standard antihypertensive medications, which must include a thiazide, thiazide-like, or loop diuretic. The study involves two parallel groups one receiving the active drug and the other receiving placebo, both as add-on therapies to current treatment. During the trial, participants will be regularly monitored for cardiovascular outcomes over approximately five years. The main measurement is the time to the first occurrence of a composite endpoint including cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or heart failure events requiring hospitalization or urgent visits. Blood pressure changes at six months and other cardiovascular outcomes will also be assessed. Safety and effectiveness will be closely observed throughout the study period.